Tau PET using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer’s disease


This study aims to evaluate the clinical validity of [18F]THK5351 PET for the assessment of disease progression and symptoms in Alzheimer’s disease (AD). Fifty one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI) and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0T MRI, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants.📍

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s